Collectively, our data suggest that NF-κB/miR-590 increased EHD1 expression to increase stem cell-like properties and EGFR-TKI resistance in lung cancer, suggesting that EHD1 may be an independent prognostic marker in lung cancer and that the NF-κB/miR-590/EHD1 signalling pathway might be a potentially effective therapy for overcoming EGFR-TKI resistance. Here, NFKB1 is linked to lung carcinoma.